Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LON-GAS
2018-004845-18Phase 3Completed
- Sponsor
- Lene Bæksgaard Jensen
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of trifluridine + tipiracil and bevacizumab in gastroesophageal junction adenocarcinoma (2 arms), sponsored by Lene Bæksgaard Jensen. Primary endpoint: Progression-free survival. Started Mar 2019; status: completed.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2018-004845-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004845-18.